Biogen
BIIB
992 hedge funds and large institutions have $50.9B invested in Biogen in 2017 Q2 according to their latest regulatory filings, with 79 funds opening new positions, 351 increasing their positions, 391 reducing their positions, and 96 closing their positions.
0.6% more ownership
Funds ownership: 87.17% → 87.77% (+0.6%)
1% less capital invested
Capital invested by funds: $51.5B → $50.9B (-$593M)
3% less funds holding
Funds holding: 1,019 → 992 (-27)
10% less repeat investments, than reductions
Existing positions increased: 351 | Existing positions reduced: 391
15% less funds holding in top 10
Funds holding in top 10: 27 → 23 (-4)
16% less call options, than puts
Call options by funds: $954M | Put options by funds: $1.14B
18% less first-time investments, than exits
New positions opened: 79 | Existing positions closed: 96
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
+$374M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$220M |
| 3 |
MNA
Manning & Napier Advisors
Fairport,
New York
|
+$183M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$179M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$148M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$355M |
| 2 |
Sands Capital Management
Arlington,
Virginia
|
-$317M |
| 3 |
Viking Global Investors
Stamford,
Connecticut
|
-$188M |
| 4 |
Invesco
Atlanta,
Georgia
|
-$184M |
| 5 |
UBS AM
Chicago,
Illinois
|
-$165M |
BIIB Hedge Fund Activity: Q2 2017 in Review
992 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Biogen (BIIB) for Q2 2017, worth a combined $50.9B — down 1.2% from $51.5B a quarter earlier.
Sellers outnumbered buyers: 96 funds closed out of BIIB and 79 opened new positions — a net loss of 17 holders — while 391 trimmed existing stakes and 351 added.
The largest buyer was Janus Henderson Group, adding an estimated $374M. The largest seller was JP Morgan Chase, cutting an estimated $355M.
- 992 institutional investors held Biogen (BIIB) as of Q2 2017, down from 1,019 in Q1 2017.
- Funds reported $50.9B of Biogen stock for Q2 2017, down 1.2% quarter-over-quarter.
- 79 funds opened new Biogen positions in Q2 2017 and 96 closed out, a net change of -17 holders.
- The largest Biogen buyer in Q2 2017 was Janus Henderson Group, an estimated $374M added.
- The largest Biogen seller in Q2 2017 was JP Morgan Chase, an estimated $355M sold.
Based on aggregated 13F filings for Q2 2017.